-
Published 7/14/2026
Berumen A, Staron A, Kalaitzidis G, Siddiqi OK, Gopal DM, Ruberg FL, Sanchorawala V. Evaluating AL-ISS within a BNP-based model for AL amyloidosis in the daratumumab era. Blood Adv. 2026 Jul 14; 10(13):4612-4616. PMID: 41995749.
-
Published 7/13/2026
Pleasure M, Jackson CL, Castillo M, DeLuca A, Kinkhabwala M, Liu Q, Chernovolenko M, Ruberg FL, Elias P, Poterucha TJ, Wats K, Brailovsky Y, Maurer MS, Johnson LL, Einstein AJ. Quantitative single photon emission computed tomography/computed tomography of Tc-99m-pyrophosphate scans: metrics for short-term risk stratification in transthyretin cardiac amyloidosis. Nucl Med Commun. 2026 Jul 13. PMID: 42438950.
-
Published 6/25/2026
Barrera NI, Ansari B, Teruya S, Fine D, Alreshq R, Ullah I, Gallegos-Kattan C, Miller E, Ruberg FL, Maurer MS. Improved Performance of Transthyretin Cardiac Amyloidosis Score by Addition of High-Sensitivity Troponin I: The SCAN-MP Study. JACC Heart Fail. 2026 Jun 25; 103221. PMID: 42360241.
-
Published 6/15/2026
Dorbala S, Maurer MS, Cuddy SAM, Auer BD, Kijewski MF, Clerc OF, Khouri MG, Mitchell JD, Sperry BW, Hanna M, AbouEzzeddine OF, Malhotra S, Wall JS, Guthrie S, Di Carli MF, Ruberg FL, Dilsizian V, Dispenzieri A, Udelson JE, Narra RK, Masri AM. Design and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis. J Nucl Cardiol. 2026 Jul; 61:102773. PMID: 42297126.
-
Published 6/1/2026
Carey P, Barrera NI, Tersalvi G, Ansari B, Alreshq R, Davies DR, Dispenzieri A, Fine D, de Freitas C, Gallegos-Kattan C, Garmany A, Grogan M, Helmke S, Miller EJ, Pellikka PA, Scott CG, Teruya S, Ullah I, Ruberg FL, Maurer MS, AbouEzzeddine OF. Diagnostic Performance of the Mayo ATTR-CM Score in Diverse Populations: Comparison With the AMY Score. JACC Adv. 2026 Jun; 5(6 Pt 2):102843. PMID: 42312781.